In particular, CAR T cells and TCR-engineered T cells have demonstrated remarkable efficacy in hematologic malignancies, with CD19-directed CAR T cells achieving durable remissions in B cell malignancies and BCMA-targeted therapies transforming the treatment landscape of multiple myeloma [27, 235, 236]. This evidence concerns the gene CD19 and hematologic disorder.